<DOC>
	<DOCNO>NCT00236418</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety topiramate add-on therapy epilepsy patient uncontrolled primary generalize tonic-clonic seizure , take 1 2 standard antiepileptic drug .</brief_summary>
	<brief_title>A Study Efficacy Safety Topiramate Epilepsy Patients With Primary Generalized Tonic-clonic Seizures</brief_title>
	<detailed_description>Epilepsy disease characterize seizure , abnormal electrical discharge brain temporarily disrupt normal brain function . Seizures classified `` generalize , '' involve brain time , `` partial onset , '' start one area brain . Generalized tonic-clonic seizure also refer grand mal seizure common people generalized epilepsy cause know . In tonic-clonic seizure , person lose consciousness , body stiffens ( tonic phase ) , individual fall ground . This follow jerking movement muscle contract relax quickly ( clonic phase ) . After minute two , jerk movement usually stop , person regains consciousness . Antiepileptic medication , topiramate , select base patient 's seizure type . Topiramate drug currently widely use treatment seizures adult pediatric patient ( 2 16 year age ) . This randomized , double-blind , parallel-group , placebo-controlled study evaluate effectiveness safety topiramate add-on therapy patient Primary Generalized Tonic-Clonic ( PGTC ) seizures . The study two phase : baseline ( 8 week ) double-blind treatment ( 20 week ) . Patients give diary record information seizures phase study . During baseline phase , patient continue receive constant dosage one two antiepileptic drug take . In double-blind phase , patient randomly assign either topiramate placebo . The double-blind phase divide two period : titration , topiramate dose gradually increase ( 8 week ) ( patient 's antiepileptic medication continue ; dose remains ) stabilization ( 12 week ) . The dose topiramate patient 's antiepileptic drug remain constant stabilization period . Based investigator 's judgment , patient complete double-blind treatment could enter long-term extension phase study continue treatment . The primary assessment effectiveness percent reduction primary generalize tonic-clonic seizure rate baseline double-blind phase . Safety assessment include frequency adverse event study , result clinical laboratory test ( hematology , biochemistry , urinalysis ) , measurement vital sign body weight , physical examination electrocardiogram ( ECG ) finding , plasma level topiramate study antiepileptic drug , neurological examination . The study hypothesis topiramate add-on superior placebo reduce seizure rate baseline double-blind phase study . Topiramate ( 25 mg 100 mg tablet ) placebo , take mouth , start dose 25 50mg/day , gradually increase maximum daily dose 175 mg 400 mg ( base body weight ) maximum tolerate dose ( whichever dose less ) . Maximum dosage continue 12 week .</detailed_description>
	<mesh_term>Seizures</mesh_term>
	<mesh_term>Epilepsy</mesh_term>
	<mesh_term>Topiramate</mesh_term>
	<criteria>Body weight &gt; 25 kilogram ( 55 pound ) diagnosis primary generalized epilepsy must primary generalized tonicclonic ( PGTC ) seizures treat 1 2 antiepileptic drug must three PGTC seizure baseline period , least 1 28day period baseline female must first menstrual period postmenopausal , physically incapable child bearing , child bear potential , sexually abstinent , use adequate birth control measure , negative pregnancy test study entry . Patients epilepsy , treatable cause seizure ( example , active infection cancer ) patient progressive disorder ( example , active infection , cancer metabolic disturbance ) patient diagnose LennoxGastaut syndrome history seizure occur cluster pattern ( numerous seizure occur short period time [ &lt; 30 minute ] ) document history ( previous 3 month ) generalize tonicclonic status epilepticus ( status epilepticus prolong seizure seizure repeat frequently 20 30 minute recovery episode occur ) receive appropriate antiepileptic medication .</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>Epilepsy</keyword>
	<keyword>Seizures</keyword>
	<keyword>Topiramate</keyword>
	<keyword>Prophylaxis</keyword>
	<keyword>Antiepileptic</keyword>
	<keyword>Tonic-clonic seizure</keyword>
	<keyword>Grand mal seizure</keyword>
</DOC>